This measure evaluates the timely administration of both Short-Acting Beta Agonists (SABAs) and corticosteroids within 60 minutes of ED presentation in pediatric patients aged 2 to 18 years experiencing moderate to severe asthma exacerbations. It specifically assesses the prompt delivery of SABAs in conjunction with oral, intramuscular (IM), or intravenous (IV) corticosteroids to ensure effective management of asthma symptoms.